PortalPublikationenHuman multipotent mesenchymal stromal cells use galectin-1 t...

Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells

Standard

Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. / Gieseke, Friederike; Böhringer, Judith; Bussolari, Rita; Dominici, Massimo; Handgretinger, Rupert; Müller, Ingo.

in: BLOOD, Jahrgang 116, Nr. 19, 11.11.2010, S. 3770-9.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Transfer › Begutachtung

Harvard

Gieseke, F, Böhringer, J, Bussolari, R, Dominici, M, Handgretinger, R & Müller, I 2010, 'Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells', BLOOD, Jg. 116, Nr. 19, S. 3770-9. https://doi.org/10.1182/blood-2010-02-270777

APA

Gieseke, F., Böhringer, J., Bussolari, R., Dominici, M., Handgretinger, R., & Müller, I. (2010). Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. BLOOD, 116(19), 3770-9. https://doi.org/10.1182/blood-2010-02-270777

Vancouver

Gieseke F, Böhringer J, Bussolari R, Dominici M, Handgretinger R, Müller I. Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. BLOOD. 2010 Nov 11;116(19):3770-9. https://doi.org/10.1182/blood-2010-02-270777

Bibtex

@article{f119db2131db44cda3222f2c1c7b4b41,
title = "Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells",
abstract = "Human multipotent mesenchymal stromal cells (MSCs) suppress proliferation and alloreactivity of T cells. Several signaling molecules and enzymes contribute to this effect. We focused on carbohydrate-protein interactions and investigated whether lectins are involved in immune modulation by MSC. Gene expression profiling of MSCs revealed that one of the most important lectins in this setting, galectin-1, was highly expressed. Galectin-1 protein was detected intracellularly and on the cell surface of MSCs. In addition, galectin-1 was released into the cell culture supernatant by MSCs. To analyze the functional role of galectin-1, a stable knockdown of galectin-1 in MSCs with use of a retroviral transfection system was established. Galectin-1 knockdown in MSCs resulted in a significant loss of their immunomodulatory properties, compared with MSCs infected with nontargeting control sequences. The galectin-1 knockdown partially restored the proliferation of CD4(+) and CD8(+) T cells. By contrast, the effect of MSCs on nonalloreactive natural killer (NK) cells was unaffected by down-regulation of galectin-1 expression. Furthermore, MSC-derived galectin-1 significantly modulated the release of cytokines involved in graft-versus-host disease (GVHD) and autoimmunity (eg, tumor necrosis factor-α [TNFα], IFNγ, interleukin-2 [IL-2], and IL-10. These results identify galectin-1 as the first lectin mediating the immunomodulatory effect of MSCs on allogeneic T cells.",
keywords = "Base Sequence, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Cell Proliferation, Cells, Cultured, Coculture Techniques, Cytokines, DNA Primers, Galectin 1, Gene Expression, Gene Knockdown Techniques, Humans, Killer Cells, Natural, Mesenchymal Stromal Cells, Multipotent Stem Cells, Stromal Cells",
author = "Friederike Gieseke and Judith B{\"o}hringer and Rita Bussolari and Massimo Dominici and Rupert Handgretinger and Ingo M{\"u}ller",
year = "2010",
month = nov,
day = "11",
doi = "10.1182/blood-2010-02-270777",
language = "English",
volume = "116",
pages = "3770--9",
journal = "BLOOD",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "19",

}

RIS

TY - JOUR

T1 - Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells

AU - Gieseke, Friederike

AU - Böhringer, Judith

AU - Bussolari, Rita

AU - Dominici, Massimo

AU - Handgretinger, Rupert

AU - Müller, Ingo

PY - 2010/11/11

Y1 - 2010/11/11

N2 - Human multipotent mesenchymal stromal cells (MSCs) suppress proliferation and alloreactivity of T cells. Several signaling molecules and enzymes contribute to this effect. We focused on carbohydrate-protein interactions and investigated whether lectins are involved in immune modulation by MSC. Gene expression profiling of MSCs revealed that one of the most important lectins in this setting, galectin-1, was highly expressed. Galectin-1 protein was detected intracellularly and on the cell surface of MSCs. In addition, galectin-1 was released into the cell culture supernatant by MSCs. To analyze the functional role of galectin-1, a stable knockdown of galectin-1 in MSCs with use of a retroviral transfection system was established. Galectin-1 knockdown in MSCs resulted in a significant loss of their immunomodulatory properties, compared with MSCs infected with nontargeting control sequences. The galectin-1 knockdown partially restored the proliferation of CD4(+) and CD8(+) T cells. By contrast, the effect of MSCs on nonalloreactive natural killer (NK) cells was unaffected by down-regulation of galectin-1 expression. Furthermore, MSC-derived galectin-1 significantly modulated the release of cytokines involved in graft-versus-host disease (GVHD) and autoimmunity (eg, tumor necrosis factor-α [TNFα], IFNγ, interleukin-2 [IL-2], and IL-10. These results identify galectin-1 as the first lectin mediating the immunomodulatory effect of MSCs on allogeneic T cells.

AB - Human multipotent mesenchymal stromal cells (MSCs) suppress proliferation and alloreactivity of T cells. Several signaling molecules and enzymes contribute to this effect. We focused on carbohydrate-protein interactions and investigated whether lectins are involved in immune modulation by MSC. Gene expression profiling of MSCs revealed that one of the most important lectins in this setting, galectin-1, was highly expressed. Galectin-1 protein was detected intracellularly and on the cell surface of MSCs. In addition, galectin-1 was released into the cell culture supernatant by MSCs. To analyze the functional role of galectin-1, a stable knockdown of galectin-1 in MSCs with use of a retroviral transfection system was established. Galectin-1 knockdown in MSCs resulted in a significant loss of their immunomodulatory properties, compared with MSCs infected with nontargeting control sequences. The galectin-1 knockdown partially restored the proliferation of CD4(+) and CD8(+) T cells. By contrast, the effect of MSCs on nonalloreactive natural killer (NK) cells was unaffected by down-regulation of galectin-1 expression. Furthermore, MSC-derived galectin-1 significantly modulated the release of cytokines involved in graft-versus-host disease (GVHD) and autoimmunity (eg, tumor necrosis factor-α [TNFα], IFNγ, interleukin-2 [IL-2], and IL-10. These results identify galectin-1 as the first lectin mediating the immunomodulatory effect of MSCs on allogeneic T cells.

KW - Base Sequence

KW - CD4-Positive T-Lymphocytes

KW - CD8-Positive T-Lymphocytes

KW - Cell Proliferation

KW - Cells, Cultured

KW - Coculture Techniques

KW - Cytokines

KW - DNA Primers

KW - Galectin 1

KW - Gene Expression

KW - Gene Knockdown Techniques

KW - Humans

KW - Killer Cells, Natural

KW - Mesenchymal Stromal Cells

KW - Multipotent Stem Cells

KW - Stromal Cells

U2 - 10.1182/blood-2010-02-270777

DO - 10.1182/blood-2010-02-270777

M3 - SCORING: Journal article

C2 - 20644118

VL - 116

SP - 3770

EP - 3779

JO - BLOOD

JF - BLOOD

SN - 0006-4971

IS - 19

ER -